XTAENXTG
Market cap8mUSD
Dec 24, Last price
88.60ILS
1D
18.61%
1Q
30.10%
Jan 2017
-95.67%
Name
Nextage Therapeutics Ltd
Chart & Performance
P/E
—
P/S
3,408.19
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
87.20%
Rev. gr., 5y
17.99%
Revenues
876k
Net income
-4m
L-35.19%
CFO
-2m
L-62.38%
Dividend
Jun 09, 200368000 ILS/sh
Earnings
Feb 20, 2025
Profile
Nextage Therapeutics Ltd develops cannabinoid-based products. The company is based in Ness Ziona, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 876 | 91 -52.36% | ||||||
Cost of revenue | 3,040 | 3,806 | 3,487 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (2,164) | (3,806) | (3,396) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (115) | 925 | ||||||
Tax Rate | ||||||||
NOPAT | (2,164) | (3,691) | (4,321) | |||||
Net income | (3,879) -35.19% | (5,985) -22.55% | (7,728) -51.60% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 1,162 | 3,443 | 4,805 | |||||
BB yield | -11.89% | -8.36% | ||||||
| Debt | ||||||||
Debt current | 308 | 211 | 232 | |||||
Long-term debt | 216 | 123 | 1,145 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 36 | 43 | 66 | |||||
Net debt | 120 | (717) | (1,886) | |||||
| Cash flow | ||||||||
Cash from operating activities | (2,262) | (6,012) | (2,409) | |||||
CAPEX | (4) | |||||||
Cash from investing activities | 3 | 17 | (5,095) | |||||
Cash from financing activities | 1,478 | 3,392 | 5,468 | |||||
FCF | (262) | (3,154) | (4,197) | |||||
| Balance | ||||||||
Cash | 404 | 1,051 | 3,263 | |||||
Long term investments | ||||||||
Excess cash | 360 | 1,051 | 3,258 | |||||
Stockholders' equity | 21,443 | (426) | 516 | |||||
Invested Capital | (2,683) | 377 | 1,413 | |||||
ROIC | 187.67% | |||||||
ROCE | 93.16% | 7,767.35% | ||||||
| EV | ||||||||
Common stock shares outstanding | 29,181 | 26,030 | ||||||
Price | 0.34 -42.44% | 0.58 -73.65% | 2.21 -28.44% | |||||
Market cap | 9,776 | 57,501 62.98% | ||||||
EV | 10,059 | 56,384 | ||||||
EBITDA | (2,036) | (3,749) | (3,206) | |||||
EV/EBITDA | ||||||||
Interest | 50 | 25 | 159 | |||||
Interest/NOPBT | ||||||||